Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FADI M KAYALI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1003031212
CMS profile
272164
Location
SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,287.59

145 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,347.59 144
Consulting Fee $940.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FADI M KAYALI

NPI 1003031212 · CMS profile ID 272164

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003031212?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FADI M KAYALI, NPI 1003031212, CMS profile ID 272164. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003031212?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). FADI M KAYALI, NPI 1003031212, CMS profile ID 272164. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003031212?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
FADI M KAYALI, NPI 1003031212, CMS profile ID 272164, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1003031212?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

145 matching records · $4,287.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 145 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 145.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $17.7507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101206870 CMS
Sumitomo Pharma America, Inc. $17.8107/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148872669 CMS
Novartis Pharmaceuticals Corporation $24.2307/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961222 CMS
Celgene Corporation $41.3407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101078452 CMS
Celgene Corporation $41.4807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101078454 CMS
AstraZeneca Pharmaceuticals LP $12.8907/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105264286 CMS
SpringWorks Therapeutics, Inc. $31.5207/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085805573 CMS
ARRAY BIOPHARMA INC $20.0407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131810149 CMS
BeiGene USA, Inc. $24.1607/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120861927 CMS
Apellis Pharmaceuticals, Inc. $17.6507/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020999 CMS
Janssen Biotech, Inc. $28.4006/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078483967 CMS
Novartis Pharmaceuticals Corporation $12.6106/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961218 CMS
E.R. Squibb & Sons, L.L.C. $18.5706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101206868 CMS
PFIZER INC. $17.4406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131352192 CMS
Gilead Sciences, Inc. $23.2906/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133830887 CMS
BeiGene USA, Inc. $24.8106/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120861925 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.8706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144960494 CMS
Eisai Inc. $33.4906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110745057 CMS
Novartis Pharmaceuticals Corporation $14.2406/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961226 CMS
E.R. Squibb & Sons, L.L.C. $19.4206/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101206864 CMS
Janssen Biotech, Inc. $0.2406/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078485186 CMS
Janssen Biotech, Inc. $17.3506/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078485566 CMS
Celgene Corporation $37.6406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101078450 CMS
Incyte Corporation $21.7506/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141213940 CMS
Daiichi Sankyo Inc. $27.4905/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089441235 CMS
Astellas Pharma US Inc $13.3605/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139359163 CMS
E.R. Squibb & Sons, L.L.C. $15.6505/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101206866 CMS
GlaxoSmithKline, LLC. $25.6605/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116614222 CMS
Alexion Pharmaceuticals, Inc. $19.9005/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094042854 CMS
PFIZER INC. $14.8805/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131521858 CMS
AstraZeneca Pharmaceuticals LP $25.5705/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104512502 CMS
E.R. Squibb & Sons, L.L.C. $19.6005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101206862 CMS
E.R. Squibb & Sons, L.L.C. $17.9305/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101206858 CMS
Novartis Pharmaceuticals Corporation $22.5805/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961212 CMS
TAIHO ONCOLOGY, INC. $18.2305/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137939784 CMS
BeiGene USA, Inc. $26.2805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120861923 CMS
Janssen Biotech, Inc. $12.6705/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078484523 CMS
AstraZeneca Pharmaceuticals LP $17.2805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105654150 CMS
Incyte Corporation $29.1305/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141180204 CMS
Merck Sharp & Dohme LLC $24.1804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141759681 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.7004/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144960492 CMS
BeiGene USA, Inc. $18.9004/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120861921 CMS
Eisai Inc. $23.2804/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110745053 CMS
Celgene Corporation $20.3704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101078444 CMS
Novartis Pharmaceuticals Corporation $18.0104/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961208 CMS
Gilead Sciences, Inc. $19.4304/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133830885 CMS
Incyte Corporation $15.4304/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141213622 CMS
Rigel Pharmaceuticals, Inc. $25.8604/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145201353 CMS
AstraZeneca Pharmaceuticals LP $21.9004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105875709 CMS
PFIZER INC. $25.8504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131294946 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,693.27 161
PY2020 $3,303.25 100
PY2021 $2,229.35 119
PY2022 $3,188.16 114
PY2023 $3,176.87 138
PY2024 $4,287.59 145
PY2025 $5,253.37 113

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $760,535.83 161
PY2024 Principal investigator $689,896.44 228
PY2023 Principal investigator $1,022,250.69 232
PY2022 Principal investigator $1,064,891.92 264
PY2021 Principal investigator $886,968.98 195
PY2020 Principal investigator $921,460.40 196
PY2019 Principal investigator $500,944.70 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

161 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $9,700.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187882232
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738993
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175322990
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 12/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223377681
Principal investigator 1 Janssen Research & Development, LLC $6,283.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175320626
Principal investigator 1 Janssen Research & Development, LLC $601.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323817
Principal investigator 1 Genentech, Inc. $2,800.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649978
Principal investigator 1 Janssen Research & Development, LLC $17,814.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175322066
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738991
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323415
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175326135
Principal investigator 1 PFIZER INC. $1,250.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228737120
Principal investigator 1 Genentech, Inc. $6,014.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652580
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321846
Principal investigator 1 Genentech, Inc. $2,800.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649939
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383110
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383112
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 11/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378053
Principal investigator 1 Daiichi Sankyo Inc. $650.00 11/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378063
Principal investigator 1 Daiichi Sankyo Inc. $1,623.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378061
Principal investigator 1 Janssen Research & Development, LLC $47.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321937
Principal investigator 1 Daiichi Sankyo Inc. $10,101.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378057
Principal investigator 1 Daiichi Sankyo Inc. $1,623.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378059
Principal investigator 1 PFIZER INC. $1,250.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228727441
Principal investigator 1 PFIZER INC. $1,250.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228737345
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738989
Principal investigator 1 Eli Lilly and Company $499.84 10/27/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187882234
Principal investigator 1 Genentech, Inc. $4,754.00 10/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652516
Principal investigator 1 AstraZeneca UK Limited $3,149.17 10/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
SERENA-2 A Randomised Open-Label Parallel-Group Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer No dispute reported 06/30/2026 1185537706
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175319230
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323069
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324260
Principal investigator 1 Janssen Research & Development, LLC $74.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324667
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325268
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175326557
Principal investigator 1 PFIZER INC. $775.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228720519
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 10/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223377679
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,600.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185537712
Principal investigator 1 Daiichi Sankyo Inc. $595.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378055
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738959
Principal investigator 1 Janssen Research & Development, LLC $10,289.00 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321384
Principal investigator 1 Daiichi Sankyo Inc. $5,733.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378051
Principal investigator 1 PFIZER INC. $1,250.00 09/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228748945
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738961
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,900.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738963
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 08/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223377671
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324453
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,936.50 08/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185537694
Principal investigator 1 PFIZER INC. $775.00 08/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228786171
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223377673
Principal investigator 1 Daiichi Sankyo Inc. $500.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223377675
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223377677
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738965
Principal investigator 1 Daiichi Sankyo Inc. $4,459.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378049
Principal investigator 1 Genentech, Inc. $906.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651681
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175326323
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228720221
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228773172
Principal investigator 1 Genentech, Inc. $156.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651690
Principal investigator 1 Genentech, Inc. $40.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651702
Principal investigator 1 Genentech, Inc. $8,476.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651955
Principal investigator 1 Genentech, Inc. $80.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652133
Principal investigator 1 Daiichi Sankyo Inc. $6,825.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378043
Principal investigator 1 Daiichi Sankyo Inc. $650.00 07/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378045
Principal investigator 1 Daiichi Sankyo Inc. $5,278.00 07/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378047
Principal investigator 1 Genentech, Inc. $23,950.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649886
Principal investigator 1 Genentech, Inc. $3,338.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211649172
Principal investigator 1 Genentech, Inc. $39.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651619
Principal investigator 1 Genentech, Inc. $51.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651638
Principal investigator 1 Genentech, Inc. $65.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651686
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651697
Principal investigator 1 Genentech, Inc. $54.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651728
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651747
Principal investigator 1 Genentech, Inc. $155.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651793
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651802
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651813
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651822
Principal investigator 1 Genentech, Inc. $56.25 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651830
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651845
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651874
Principal investigator 1 Genentech, Inc. $65.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651981
Principal investigator 1 Genentech, Inc. $125.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652044
Principal investigator 1 Genentech, Inc. $39.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652073
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652099
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652103
Principal investigator 1 Genentech, Inc. $125.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652189
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652203
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652241
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652247
Principal investigator 1 Genentech, Inc. $63.75 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652253
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652309
Principal investigator 1 Genentech, Inc. $49.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652314
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652328
Principal investigator 1 Genentech, Inc. $49.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651712
Principal investigator 1 Genentech, Inc. $6,014.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652028
Principal investigator 1 Genentech, Inc. $51.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652174
Principal investigator 1 Genentech, Inc. $6,014.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652199
Principal investigator 1 Genentech, Inc. $54.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652325
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738967
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323275
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325209
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 06/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383106
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 06/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383108
Principal investigator 1 PFIZER INC. $1,250.00 06/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228777428
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,300.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185537702
Principal investigator 1 AstraZeneca UK Limited $87,488.67 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185537698
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738969
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738971
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738973
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738975
Principal investigator 1 Daiichi Sankyo Inc. $650.00 05/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378033
Principal investigator 1 Daiichi Sankyo Inc. $5,915.00 05/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378035
Principal investigator 1 Daiichi Sankyo Inc. $4,823.00 05/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378037
Principal investigator 1 Daiichi Sankyo Inc. $4,004.00 05/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378039
Principal investigator 1 Daiichi Sankyo Inc. $390.00 05/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378041
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,763.41 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185537714
Principal investigator 1 BeiGene, Ltd. $84.20 05/19/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190320758
Principal investigator 1 PFIZER INC. $1,250.00 05/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228764557
Principal investigator 1 ABBVIE INC. $2,775.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202480931
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,126.66 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
SERENA-2 A Randomised Open-Label Parallel-Group Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer No dispute reported 06/30/2026 1185537692
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,013.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185537700
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,250.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185537718
Principal investigator 1 AstraZeneca Pharmaceuticals LP $111,997.30 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185537722
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,841.95 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185537724
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738977
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738979
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 04/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383102
Principal investigator 1 Genentech, Inc. $11,592.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650887
Principal investigator 1 PFIZER INC. $775.00 04/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228780149
Principal investigator 1 AstraZeneca UK Limited $28,582.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185537720
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 04/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383100
Principal investigator 1 Daiichi Sankyo Inc. $2,125.00 04/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383104
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,125.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738981
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738983
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738985
Principal investigator 1 AstraZeneca UK Limited $10,944.00 03/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185537708
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 03/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
U31402-A-U301 No dispute reported 06/30/2026 1223383098
Principal investigator 1 PFIZER INC. $1,250.00 03/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228781294
Principal investigator 1 Genentech, Inc. $51.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650294
Principal investigator 1 Genentech, Inc. $54.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650347
Principal investigator 1 Genentech, Inc. $49.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650402
Principal investigator 1 Genentech, Inc. $49.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650428
Principal investigator 1 Genentech, Inc. $65.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650461
Principal investigator 1 Genentech, Inc. $65.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650517
Principal investigator 1 Genentech, Inc. $51.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650547
Principal investigator 1 Genentech, Inc. $39.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650551
Principal investigator 1 Genentech, Inc. $54.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650718
Principal investigator 1 Genentech, Inc. $155.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650734
Principal investigator 1 Genentech, Inc. $39.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650738
Principal investigator 1 Genentech, Inc. $40.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650872
Principal investigator 1 PFIZER INC. $1,250.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228719737
Principal investigator 1 PFIZER INC. $775.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228788172
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738987
Principal investigator 1 Daiichi Sankyo Inc. $1,801.80 01/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223377937
Principal investigator 1 AstraZeneca UK Limited $3,200.00 01/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185537716
Principal investigator 1 Genentech, Inc. $14,712.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650467
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,410.44 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185537696
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,036.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185537710
Principal investigator 1 Mirati Therapeutics, Inc. $79,955.89 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530625
Principal investigator 1 PFIZER INC. $1,250.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228724840
Principal investigator 1 PFIZER INC. $775.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228799580